Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 2141 V-11 |
Synonyms | |
Therapy Description |
2141 V-11 is a human anti-CD40 antibody with modified Fc domain, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 30297432). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
2141 V-11 | 2141 V11|2141-V11 | CD40 Antibody 14 | 2141 V-11 is a human anti-CD40 antibody with modified Fc domain, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 30297432). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06347705 | Phase II | 2141 V-11 | A Study of 2141-V11 in Combination With Standard Treatments in People With Prostate Cancer | Recruiting | USA | 0 |
NCT05126472 | Phase I | 2141 V-11 | Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment | Recruiting | USA | 0 |
NCT04059588 | Phase I | 2141 V-11 | A Study Investigating the Safety and Tolerability of an Immune Treatment in Cancer Patients With Lesions to the Skin | Completed | USA | 0 |